Roche buys precision medicine company Ignyta for $1.7bn
Roche acquired publicly traded, precision oncology medicine company Ignyta Inc. for $27 per share in cash (a 73% premium), or a total of $1.7bn enterprise value factoring in the latest net debt ($1.8bn equity value).
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com